# Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin? {% hint style="warning" %} ### Short answer For **HER2-positive, ERα-positive** breast cancer, especially **Luminal B** or **triple-positive** disease, **resveratrol and polydatin should not be treated as casual self-directed adjuncts**. This is not a blanket ban. It is a real caution based on a specific **Δ16HER2** breast-cancer signal. That signal has not been confirmed in human trials. {% endhint %} The key question is not whether these compounds are always good or always bad. The key question is how they may behave in a very specific **HER2-positive, ER-positive breast-cancer context**. This page gives the short practical answer first. It then points to the deeper mechanism pages for readers who want the full context. ### Why the concern exists The main caution comes from **resveratrol**, not from a direct human polydatin trial. In a **Δ16HER2 transgenic breast-cancer mouse model**, resveratrol accelerated tumour development instead of suppressing it. Reported findings included: * earlier tumour onset * more tumours per mouse * stronger proliferative signalling * activation of the **mTORC1 / p70S6K / 4EBP1** pathway * marked reduction in **ERα** expression This matters because **polydatin is metabolised toward resveratrol**. That does not prove polydatin behaves identically in patients. It does mean the resveratrol signal cannot be ignored in this subtype. ### Why Luminal B and HER2+/ERα+ context matter This caution is strongest in **HER2-positive breast cancer with hormone-receptor signalling still in play**. That includes **HER2+/ERα+** and many **triple-positive** settings. It matters even more when the biology looks **Luminal B-like**, where HER2 and estrogen signalling can overlap in unstable ways. The issue is not HER2 positivity alone. The issue is the combination of: * **HER2-driven signalling** * **ERα-related signalling** * the possible presence of **Δ16HER2** * a compound family linked to **resveratrol** ### What this means for polydatin Polydatin still has meaningful anticancer findings in breast-cancer research. It shows apoptosis, CREB suppression, PI3K/Akt and MAPK effects, and stronger signals in **TNBC** than in HER2-positive disease. But HER2-positive breast cancer is the one subtype where its conversion toward resveratrol becomes a specific caution, not just a theoretical footnote. So the practical position is: * **do not assume polydatin is safe just because it is not plain resveratrol** * **do not assume the warning applies to every HER2-positive tumour equally** * **do not use either as a casual add-on without clinician review** ### What we can say honestly #### What looks real * There is a peer-reviewed **Δ16HER2** warning signal in **HER2-positive, ER-positive breast cancer** * That signal is relevant to **resveratrol** * Because polydatin converts toward resveratrol, the caution carries over enough to matter clinically #### What remains uncertain * We do not know that every **HER2-positive** tumour expresses clinically meaningful **Δ16HER2** * We do not know that polydatin has the same net effect as resveratrol in living patients * We do not have human oncology trials proving harm from resveratrol or polydatin in this setting ### Practical takeaway If the question is, **"Should a HER2+/ERα+ patient avoid resveratrol or polydatin?"**, the cleanest answer is: **They should avoid treating them as routine or low-risk supplements.** That is stronger than simple uncertainty. It is weaker than a proven blanket contraindication. For **HER2-positive, ER-positive, Luminal B-like, or triple-positive** disease, this is a **discuss first** compound pair. For patients outside that exact context, the warning becomes less certain and more subtype-dependent. ### Read next * [HER2+ Cancers](/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/her2+-cancers.md) — the deeper polydatin-specific caution page * [Breast Cancer](/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/breast-cancer.md) — the wider polydatin breast-cancer evidence page * [Triple-Positive](/myhealingcommunity-docs/breast-cancer/triple-positive.md) — for the overlap between HER2 and hormone-receptor biology * [Distinguishing Luminal A from Luminal B](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/distinguishing-luminal-a-from-luminal-b.md) — for the subtype context behind this caution ### References Resveratrol fuels HER2 and ERα-positive breast cancer behaving as an oncogenic compound in Δ16HER2 transgenic mice — Andreani, Bartolacci et al., *Aging*, 2017\ The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers — *Cancers*, 2019\ HER2 isoforms co-expression differently tunes mammary tumour phenotypes — *Oncotarget*, 2017\ Polydatin down-regulates the phosphorylation level of CREB and induces apoptosis in human breast cancer cells\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/her2-positive/should-her2+-era+-patients-avoid-resveratrol-or-polydatin.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.